<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1132">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146414</url>
  </required_header>
  <id_info>
    <org_study_id>CRC18058</org_study_id>
    <nct_id>NCT05146414</nct_id>
  </id_info>
  <brief_title>Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus</brief_title>
  <acronym>HEMATOPLUS</acronym>
  <official_title>Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr Nathalie COSTEDOAT-CHALUMEAU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE) is not fully&#xD;
      explained by Framingham risk factors. The detection in asymptomatic patients of somatic&#xD;
      mutations in genes involved in hematopoietic malignancy- defining clonal hematopoiesis of&#xD;
      indeterminate potential (CHIP) - predisposes to cardiovascular events (CVE) in general&#xD;
      population. We aimed to determine whether CHIP is associated with CVE in SLE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLE patients indeed display an accelerated atherosclerosis that strongly contributes to the&#xD;
      excess mortality observed but is poorly explained by the traditional cardiovascular risk&#xD;
      factors. Clonal hematopoiesis defines the clonal expansion of hematopoietic cells driven by a&#xD;
      selective advantage given by leukemia-associated somatic mutations. Clonal hematopoiesis is&#xD;
      said of indeterminate potential (CHIP) when found in asymptomatic patient. CHIP strongly&#xD;
      correlated with age and logically predispose to haematological malignancy, but is also&#xD;
      causally associated with cardiovascular events (CVE) in the general population. The main&#xD;
      objective of our study was to determine whether CHIP is associated with CVE in SLE patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2007</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome was the occurrence of cardiovascular events (CVE) over follow-up.</measure>
    <time_frame>&gt;20 months after PLUS inclusion</time_frame>
    <description>Incidents CVE were ascertained by physician interview using a standardized questionnaire and through examination of medical records. CVE included coronary heart disease, stroke, revascularization procedure for other atherosclerotic cardiovascular diseases and sudden cardiac death. Coronary heart disease was defined as a history of angina, coronary revascularization, or myocardial infarction. All CVE that occurred through March 2019 were considered for analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of CHIP in SLE</measure>
    <time_frame>at PLUS inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a systemic lupus erythematosus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a systemic lupus erythematosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate follow-up period (&lt; 20 months) -past history of CVE at baseline for&#xD;
             inclusion in the TROPOPLUS study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim SACRE, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H么pital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Clonal hematopoiesis of indeterminate potential</keyword>
  <keyword>Cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

